Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy

The benefit of adjuvant trastuzumab in disease-free and overall survival for human epidermal receptor 2–positive (HER2+) breast cancer patients is well established. However, the effect of trastuzumab on locoregional control remains unclear, particularly in patients treated with adjuvant radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Lu, Cai, Gang, Xu, Fei, Yang, Zhao-Zhi, Yu, Xiao-Li, Ma, Jin-Li, Zhang, Qian, Wu, Jiong, Guo, Xiao-Mao, Chen, Jia-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985293/
https://www.ncbi.nlm.nih.gov/pubmed/27512838
http://dx.doi.org/10.1097/MD.0000000000004230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985293/
https://www.ncbi.nlm.nih.gov/pubmed/27512838
http://dx.doi.org/10.1097/MD.0000000000004230

Ejemplares similares